BRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioRestorative Therapies Inc (BRTX) is not a good buy at the moment for a beginner investor with a long-term strategy. The stock is experiencing significant bearish momentum, with a sharp decline in price, weak financial performance, and no strong positive catalysts to offset the risks. The recent public offering at a higher price than the current market price suggests dilution concerns, and the technical indicators point to continued downward pressure.
The technical indicators are bearish. The MACD histogram is negative and expanding downward, the RSI is extremely oversold at 3.487, and the moving averages indicate a strong bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading well below key support levels, with the next support at 0.17.
The company had a successful meeting with the FDA discussing an accelerated approval pathway for BRTX-100, with positive safety outcomes in ongoing trials.
The stock experienced a sharp decline of over 40% in regular trading and an additional 39.41% drop in pre-market trading. The public offering of 14.3 million shares at $0.35 dilutes existing shareholders and raises concerns about the company's financial health. The financial performance shows a significant revenue drop (-94.95% YoY) and negative net income, despite some improvement in EPS and net loss.
In Q3 2025, revenue dropped significantly by -94.95% YoY to $11,800. Net income improved to -$3,038,277 (up 178.38% YoY), and EPS improved to -0.33 (up 153.85% YoY). Gross margin fell sharply by -88.70% YoY to 10.42%. Overall, the financials indicate a struggling company with limited growth.
No recent analyst rating or price target changes are available.
